SCHEMBL2932159

SCHEMBL2932159

O=C(NCCn1cc2c(-c3ccc(F)cc3)c(-c3ccncc3)c(-c3ccc(F)cc3)nc2n1)C1CCNCC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.40
ADORA2B P29275 1/20 0.40
ADORA1 P30542 1/20 0.40
CSNK1D P48730 6/20 0.40
CSNK1E P49674 6/20 0.40
MAPK14 Q16539 7/20 0.39
MAPK11 Q15759 4/20 0.39
PLK1 P53350 1/20 0.38
MAPK13 O15264 2/20 0.38
MAPK12 P53778 2/20 0.38
RAF1 P04049 1/20 0.38
MAPK9 P45984 1/20 0.38
KCNH2 Q12809 1/20 0.37
APOL1 O14791 1/20 0.37
HTR3A P46098 1/20 0.37
GSK3B P49841 2/20 0.37
RIPK3 Q9Y572 1/20 0.36
ABL1 P00519 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1386175 0.87 CSNK1D (0.42) ADORA2AADORA2BADORA1CSNK1DCSNK1E
SCHEMBL1384346 0.85 MAPK14 (0.42) CSNK1DCSNK1EMAPK14MAPK11MAPK13
SCHEMBL2925785 0.85 NAMPT (0.41) CSNK1DCSNK1EMAPK14MAPK11KCNH2
SCHEMBL2929429 0.83 MAPK14 (0.45) CSNK1DCSNK1EMAPK14MAPK11MAPK13
SCHEMBL2931870 0.82 MAPK14 (0.44) ADORA2AADORA2BADORA1CSNK1DCSNK1E
SCHEMBL2929818 0.82 MAPK14 (0.43) ADORA2AADORA2BADORA1CSNK1DCSNK1E
SCHEMBL2930511 0.82 MAPK14 (0.42) ADORA2AADORA2BADORA1CSNK1DCSNK1E
SCHEMBL2926478 0.82 MAPK14 (0.43) CSNK1DCSNK1EMAPK14MAPK11MAPK13
SCHEMBL2930642 0.81 MAPK14 (0.42) CSNK1DCSNK1EMAPK14MAPK11MAPK13
SCHEMBL1385787 0.80 RIPK3 (0.48) ADORA2AADORA2BADORA1CSNK1DCSNK1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 ADORA2A 3463/4885ADORA2B 4238/4885ADORA1 4004/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 ADORA2A 3970/4885ADORA2B 4436/4885ADORA1 4368/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 ADORA2A 3970/4885ADORA2B 4436/4885ADORA1 4368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.